OncoHost Secures Major Grant for Precision Oncology Developments
OncoHost, a pioneering technology company in the field of precision medicine, has recently announced a significant milestone in its journey. Together with prominent partners in the medical field, OncoHost has been awarded a notable grant of €2.5 million from the EIC Transition Program. This funding will bolster the company’s ongoing research efforts aimed at advancing precision oncology for patients receiving immunotherapy.
The Collaborative Effort for Groundbreaking Research
The grant, obtained as part of a consortium with esteemed institutions like Heidelberg University Hospital and the European Institute of Oncology, will facilitate the development of an innovative biomarker that predicts how different cancer types respond to immunotherapy. This initiative will focus on five major indications: Non-small cell lung cancer (NSCLC), Renal cell carcinoma (RCC), Melanoma, Head and Neck squamous cell carcinoma (HNSCC), and Triple negative breast cancer. The project is set to be coordinated by OncoHost.
The Promise of Predictive Biomarkers
Despite the advancements in immuno-oncology, the challenge of identifying which patients benefit most from immune checkpoint inhibitors remains significant. OncoHost aims to address this issue head-on by expanding its proprietary profiling platform, PROphet®, which is designed to produce reliable predictive biomarkers. This endeavor is crucial considering the necessity for tailored approaches in cancer treatment.
Groundbreaking Developments in Biomarker Identification
A recent study has emphasized the potential of Ly6Ehi neutrophils in blood samples as a strong biomarker for predicting patient responses to immune checkpoint inhibitors. These findings pave the way for a more personalized approach to cancer treatment, reducing uncertainty in clinical decision-making.
Leading figures in the consortium express excitement about the grant's implications. Professor Francesco Bertolini from the European Institute of Oncology highlighted the unique opportunity this funding provides to translate promising preclinical research into validated clinical applications.
Introducing NeutroFlow: A New Testing Method
In line with this groundbreaking research, the consortium plans to develop NeutroFlow, a novel test that promises simplicity and rapid results for predicting patient responses to treatment. Utilizing flow cytometry, a widely available method in medical centers, this test aims to provide an efficient and cost-effective way to evaluate therapeutic benefits. OncoHost’s commitment to improving patient care resonates through this innovative approach.
Collaborative Efforts to Enhance Patient Outcomes
Professor Petros Christopoulos of Heidelberg University expressed optimism about NeutroFlow's potential to integrate a cell-based biomarker into routine clinical practice, furthering the goal of personalized medicine.
Dr. Alberto Moreno from Virgen Macarena University Hospital emphasized the project’s importance, stating that it would facilitate the rapid clinical validation of this promising biomarker across various cancers. This collaboration among multidisciplinary teams is instrumental in ensuring that research insights are swiftly translated into practical solutions for clinicians and patients alike.
The EIC Transition Program and Its Objectives
The EIC Transition is a pivotal funding initiative under Horizon Europe, the European Union's primary program for research and innovation. It focuses on innovative projects that extend beyond laboratory proof-of-concept, cultivating mature technologies ready for real-world applications. This strategic approach not only enhances technological development but also aligns with OncoHost's mission to revolutionize precision medicine.
About OncoHost
OncoHost, with its headquarters in Binyamina, Israel, and Cary, North Carolina, has established itself as a leader in transforming precision medicine. The company’s flagship platform, PROphet®, utilizes proteomic pattern analysis to guide immunotherapy decisions, underscoring its commitment to enhancing patient outcomes. The PROphetNSCLC™ test epitomizes clinical utility by equipping physicians with essential insights for tailoring treatment strategies effectively. Backed by a robust team of industry experts and extensive clinical trials encompassing over 1,700 patients, OncoHost is poised to elevate the standards of precision diagnostics and biomarker development.
Frequently Asked Questions
What is the purpose of the €2.5 million grant awarded to OncoHost?
The grant aims to support the development of a novel biomarker for predicting responses to immunotherapy in various cancer types.
Which partners are involved in the OncoHost grant project?
The project involves collaborators such as Heidelberg University Hospital and the European Institute of Oncology, among others.
What technology will NeutroFlow utilize for its testing methods?
NeutroFlow will use flow cytometry for rapid and effective predictions of patient responses to immunotherapy treatments.
How will this research impact clinical practices?
This research aims to translate innovative findings into clinical settings, ensuring better treatment options and personalized care for cancer patients.
What is the significance of the EIC Transition Program?
The EIC Transition Program funds innovative activities that advance technologies from laboratory work to real-world applications, fostering research and development efforts.
